EUVIMEDEUVIMED entdecken
Crossref

The metabolic profile of lean patients with esophageal adenocarcinoma and Barrett’s esophagus

Tarek Sawas, Joanne T Benson, Alina Allen, Kenneth Wang, Sachin Wani, Prasad G Iyer, David A Katzka

Diseases of the Esophagus · 2025

DOI: 10.1093/dote/doaf080 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Diseases of the Esophagus, 2025. Verfasst von Tarek Sawas und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Digestive and Liver Diseases, University of Texas Southwestern, Dallas, TX, USA. Hauptthemen laut MEDLINE: Barrett Esophagus, Esophageal Neoplasms, Adenocarcinoma, Thinness. Die Arbeit nennt 37 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Central obesity is a risk factor for esophageal adenocarcinoma (EAC) independent of acid reflux. However, about a quarter of patients with Barrett’s esophagus (BE) and EAC have a normal body mass index (BMI). One hypothesis is that chronic systemic inflammation is as critical to the cancer pathway than the BMI alone. Therefore, we hypothesized that lean patients with BE/EAC would have a high prevalence of metabolic diseases. We aimed to compare metabolic diseases among lean patients with BE/EAC and overweight/obese BE/EAC and lean control without BE/EAC. We performed a propensity score–matched case–control study including patients with BE/EAC and a control group without BE/EAC from the Rochester Epidemiology Project (REP). The groups were compared using chi-square χ 2 and Student t-test as appropriate. Adjusted logistic regression models were used to compare the association with metabolic diseases. We included a total of 2504 patients (631 EAC, 621 BE, and 1252 controls). A quarter of patients (24.6%) with BE/EAC were lean. When compared to controls without BE/EAC, lean patients with BE were more likely to have diabetes (32.2% vs. 11.2%, P < 0.001) and hyperlipidemia (76.2% vs. 53%, P < 0.001). When comparing lean EAC patients to controls without BE/EAC, lean patients had a higher association with smoking (73.3% vs. 58.6%, P: 0.002) and diabetes (18.7% vs. 11.2%, P: 0.03). When compared to overweight/obese BE patients, lean BE were less likely to have NASH (7.7% vs. 20.3%, P: 0.001), diabetes (32.3% vs. 42.1%, P: 0.03), hyperlipidemia (77.2% vs. 87%, P: 0.003), and metabolic syndrome (24% vs. 54%, P < 0.001). Similarly, when compared to overweight/obese patients with EAC, lean EAC patients were less likely to have NASH (0% vs. 15.5%, P < 0.001), diabetes (18.7% vs. 34.1%, P < 0.001), hyperlipidemia (37.3% vs. 51.8%, P: 0.002), hypertension (37.3% vs. 55.3%, P < 0.001), and metabolic syndrome (8% vs. 37.6%, P < 0.001). A quarter of patients with BE/EAC are lean. Although lean BE/EAC patients have a more favorable metabolic profile compared to overweight/obese BE/EAC patients, diabetes and smoking are more common among lean patients with EAC compared to lean controls. The higher association with smoking and diabetes among lean EAC challenges traditional risk factor paradigms, suggesting a significant role for insulin resistance and chronic inflammation in EAC pathogenesis, especially in patients without typical risk factors. BMI-determined obesity may need to be supplemented with inflammatory metabolic diseases to improve assessment of BE/EAC risk in lean patients.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Barrett EsophagusEsophageal NeoplasmsAdenocarcinomaThinnessMetabolomeMetabolic DiseasesHumansMaleFemaleCase-Control StudiesMiddle AgedAgedBody Mass IndexObesityRisk FactorsHyperlipidemiasPropensity ScoreLogistic ModelsOverweightDiabetes MellitusMetabolic Syndrome

Stichwörter der Autor:innen

Barrett’s esophagusesophageal adenocarcinomaleanmetabolic diseases

Autor:innen und Institutionen

  • Division of Digestive and Liver Diseases, University of Texas Southwestern, Dallas, TX, USA.
  • Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
  • Barrett's Esophagus Unit, Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, USA.
  • Division of Gastroenterology and Hepatology, University of Colorado Anschutz Medical Campus, Aurora, CO, USA.
  • Division of Gastroenterology and Hepatology, Columbia University, New York, NY, USA.

Zitieren

APA

Sawas, T., Benson, J. T., Allen, A., Wang, K., Wani, S., Iyer, P. G., & Katzka, D. A. (2025). The metabolic profile of lean patients with esophageal adenocarcinoma and Barrett’s esophagus. Diseases of the Esophagus. https://doi.org/10.1093/dote/doaf080

Vancouver

Sawas T, Benson JT, Allen A, Wang K, Wani S, Iyer PG, et al. The metabolic profile of lean patients with esophageal adenocarcinoma and Barrett’s esophagus. Diseases of the Esophagus. 2025. doi:10.1093/dote/doaf080

BibTeX
@article{Sawas2025,
  author = {Sawas, Tarek and Benson, Joanne T and Allen, Alina and Wang, Kenneth and Wani, Sachin and Iyer, Prasad G and Katzka, David A},
  title = {The metabolic profile of lean patients with esophageal adenocarcinoma and Barrett’s esophagus},
  journal = {Diseases of the Esophagus},
  year = {2025},
  doi = {10.1093/dote/doaf080}
}
Kostenlos starten →